3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Glioblastoma
101
Glioma
43
Brain Neoplasms
28
Neuroblastoma
25
Astrocytoma
19
Gliosarcoma
15
Sarcoma, Ewing
12
Rhabdomyosarcoma
12
Neoplasms
12
Recurrence
11
Medulloblastoma
11
Sarcoma
9
Small Cell Lung Carcinoma
8
Oligodendroglioma
8
Melanoma
7
Osteosarcoma
6
Ependymoma
6
Diffuse Intrinsic Pontine Glioma
6
Central Nervous System Neoplasms
4
Rhabdoid Tumor
3
Prostatic Neoplasms
3
Neuroendocrine Tumors
3
Neuroectodermal Tumors, Primitive
3
Neoplasm Metastasis
3
Lymphoma, Follicular
3
Lymphoma
3
Lung Neoplasms
3
Ganglioneuroblastoma
3
Desmoplastic Small Round Cell Tumor
3
Colorectal Neoplasms
3
Interventions
lutetium Lu 177 dotatate
6
Octreotide
3
pasireotide
2
lanreotide
2
gallium Ga 68 dotatate
2
copper dotatate CU-64
2
amino-acid, glucose, and electrolyte solution
2
Magnetic Resonance Spectroscopy
2
Lutetium-177
2
Lutetium
2
Ga(III)-DOTATOC
2
Everolimus
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
zimberelimab
1
irinotecan sucrosofate
1
abemaciclib
1
X-Rays
1
Temozolomide
1
Sunitinib
1
Receptor-Like Protein Tyrosine Phosphatases, Class 2
1
Radiosurgery
1
PM 01183
1
Oxaliplatin
1
Nivolumab
1
Leucovorin
1
Irinotecan
1
Ipilimumab
1
Folfox protocol
1
Fluorouracil
1
E-7386
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
Temozolomide
×
1 year
×
Clear all
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled